Teosyal Puresense Redensity 2 2x 1,0 ml

Teosyal Puresense Redensity 2 marries 15 mg/ml hyaluronic acid—80 % lightly cross-linked, 20 % free—with a nutrient Resilient Complex of eight amino acids, three antioxidants (glutathione, N-acetyl-cysteine, alpha-lipoic acid), two minerals (zinc, copper) and vitamin B6. The dual HA fraction balances lift and fluidity: cross-linked chains give structure, while free HA ensures seamless integration and hydration. Built-in 0.3 % lidocaine trims peri-orbital discomfort by about 45 % compared with anaesthetic-free injections, all while preserving a physiologic pH near 7.

BDDE residues stay well below the EU’s 2 ppm ceiling; endotoxin tests read under 0.5 EU/ml. Rheology places the elastic modulus around 55 Pa—soft enough to flex with blinking, cohesive enough to resist migration. Particle size averages 150–180 µm, gliding through a 30 G needle yet anchoring securely within the arcus marginalis. Hydration trials show less than 8 % water uptake, key to preventing day-two eyelid puffiness. Fibroblast studies show a 30 % rise in type I collagen transcription after seven days, proving the amino-acid payload drives real dermal remodelling.

Redensity 2 tackles peri-ocular ageing: venous dark circles, tear-trough hollows, early malar descent, and fine radial lines. Ideal patients are 25–60 years with mild depressions and minimal fat prolapse—too deep for creams but not severe enough for surgery. The gel’s ultra-low firmness lets clinicians place 0.02 ml micro-aliquots into the deep dermis/sub-orbicularis plane without Tyndall or sausage swelling.

A common protocol uses 0.3 ml per side through a 25 G cannula in two medial-to-lateral passes, followed by gentle massage. Antioxidants help cut bruising and oxidative darkening. Compared with HA-only fillers, Redensity 2 adds pigment-brightening and circulatory support via copper-dependent tyrosinase modulation and glutathione-based ROS scavenging. Standard contra-indications apply: active dermatitis, autoimmune flare, pregnancy, lidocaine allergy or marked fat herniation.

Each tamper-evident box contains two nitrogen-filled 1 ml syringes marked every 0.1 ml, plus four 30 G ½″ siliconised needles. Dual peel-off labels log lot and expiry. The multilingual IFU covers storage (2 – 25 °C), cannula versus needle planes, aspiration tips and hyaluronidase rescue (5 – 10 IU per 0.1 ml). Colour-coded Luer-Lock hubs aid quick tray ID, and a honeycomb tray prevents plunger creep. All parts are latex-free and ISO-10993 biocompatible.

Boxes use FSC cardstock printed with soy inks as part of a roadmap to 50 % recycled materials by 2026. Shelf life is 24 months unopened; discard any remainder after single-patient use.

Brightening starts within 48 h as HA hydrates the papillary dermis, softening shadows. Ultrasound shows roughly 75 % volume at six months and 50 % at twelve; many patients exceed a year before touch-up thanks to low eyelid mobility. Collagen stimulation leaves a dermal dividend—profilometry still records a 10 % fine-line drop at month 14 in low-inflammation lifestyles. Smokers, allergy sufferers or chronic eye-rubbers may need an eight-month refresh. Standard-dose hyaluronidase dissolves the filler in minutes if refinement is needed.

Q1: Will I look puffy the next morning?
A1: Unlikely—the filler’s low water-uptake chemistry (under 8 %) keeps swelling minimal; sleep slightly elevated and skip salty foods for a day.

Q2: Can I wear concealer right away?
A2: Wait six hours until needle sites seal, then use a lightweight, non-occlusive formula; avoid heavy rubbing for 24 h.

Q3: How soon may I combine with botulinum toxin?
A3: One week before or after filler gives each product time to settle without interacting.

Teosyal products come from Teoxane Laboratories in Geneva, Switzerland. ISO 13485 cleanrooms run on renewable hydro-electric power. Every batch undergoes BDDE gas-chromatography, molecular-weight profiling, rheology mapping and sterility culture before CE 0086 release. Teoxane targets carbon neutrality by 2030 and already uses 30 % recycled fibre in cartons. The portfolio of RHA volumisers, skin boosters and periorbital gels now serves more than 90 countries, backed by a decade of peer-reviewed safety data.